Journal of Oncology Pharmacy Practice

Papers
(The H4-Index of Journal of Oncology Pharmacy Practice is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings55
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class38
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors28
Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department26
Cancer patient experience of telephone clinics implemented in light of COVID-1925
A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide24
Cross-sectional evaluation of surface contamination with 9 antineoplastic drugs in 93 Canadian healthcare centers: 2019 results19
Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab18
ISOPP Standards for the Safe Handling of Cytotoxics17
Factors affecting health-related quality of life among prostate cancer patients: A systematic review17
Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial16
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations15
Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab15
Pegfilgrastim-associated large-vessel vasculitis developed during adjuvant chemotherapy for breast cancer: A case report and review of the literature15
Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. The first case report of bystander effect on bone14
Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?14
Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases14
0.048260927200317